GIM
STOK icon

Generali Investments Management’s Stoke Therapeutics STOK Stock Holding History

Generali Investments Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.08M Buy
33,149
+26,237
+380% +$842K 0.24% 72
2026
Q1 		$225K Buy
6,912
+4,441
+180% +$146K 0.05% 130
2025
Q4 		$78.4K Buy
2,471
+718
+41% +$21.6K 0.02% 153
2025
Q3 		$41.2K Buy
+1,753
New +$30K 0.01% 171

Other funds holding STOK

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
DWM
Dogwood Wealth Management Lenexa, Kansas $253M AUM 19.41% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

Generali Investments Management's STOK Position: Q2 2026 in Review

Generali Investments Management increased its Stoke Therapeutics (STOK) stake by 380% in Q2 2026, buying an estimated $842K and bringing the position to 33,149 shares worth $1.08M. The position accounts for 0.24% of the portfolio, ranked #72.

Generali Investments Management first reported a position in STOK in Q3 2025 and has held it in 4 quarters since. 8 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Generali Investments Management held 33,149 shares of Stoke Therapeutics worth $1.08M as of Q2 2026.
  • Generali Investments Management bought 26,237 Stoke Therapeutics shares in Q2 2026, an estimated $842K.
  • Stoke Therapeutics made up 0.24% of Generali Investments Management's portfolio in Q2 2026, its #72 holding.
  • Generali Investments Management first reported a position in Stoke Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 8 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Generali Investments Management's 13F filing for Q2 2026, filed 10 Jul 2026.